Neidhart J A, Gagen M, Young D, Wilson H E
Cancer. 1981 Mar 15;47(6):1439-43. doi: 10.1002/1097-0142(19810315)47:6<1439::aid-cncr2820470633>3.0.co;2-#.
Sixty-four patients receiving cancer chemotherapy known to induce severe emesis entered a randomized double-blind study of the antiemetic efficacy of haloperidol (Haldol) and benzquinamide (Emetecon). Patients preferred haloperidol for control of emesis induced by cis-platinum (78 vs. 22%) or nitrogen mustard (67 vs. 16%). Patients receiving Doxorubicin preferred benzquinamide by a small margin (46 to 38%). Individual patients who experienced no relief with their first antiemetic (13 of 15) usually got some relief with the other after crossover. Haloperidol was more effective than benzquinamide (54 vs. 29%) in patients previously unrelieved by prochlorperazine (Compazine). Complete relief of vomiting was obtained in 14 of 45 patients receiving haloperidol but only five of 41 patients receiving benzquinamide experienced no vomiting, again dependent on the anticancer agent used. Although haloperidol is a more effective antiemetic agent overall, efficacy is related to the anticancer treatment and probably to individual patient characteristics.
64名接受已知会引发严重呕吐的癌症化疗患者进入了一项关于氟哌啶醇（哈力多）和苄喹酰胺（止呕灵）止吐疗效的随机双盲研究。在控制顺铂（78%对22%）或氮芥（67%对16%）引发的呕吐方面，患者更倾向于氟哌啶醇。接受阿霉素治疗的患者对苄喹酰胺的偏好略高（46%对38%）。在首次使用止吐药后未缓解的个体患者（15例中的13例），交叉使用另一种药物后通常会有所缓解。在先前使用丙氯拉嗪（康帕嗪）未缓解的患者中，氟哌啶醇比苄喹酰胺更有效（54%对29%）。接受氟哌啶醇治疗的45名患者中有14名完全缓解了呕吐，但接受苄喹酰胺治疗的41名患者中只有5名没有呕吐，同样取决于所使用的抗癌药物。虽然总体而言氟哌啶醇是一种更有效的止吐药，但其疗效与抗癌治疗有关，可能也与个体患者特征有关。
